Clinical Trials Logo

Hemophilia A, Congenital clinical trials

View clinical trials related to Hemophilia A, Congenital.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03095287 Terminated - Clinical trials for Hemophilia A, Congenital

Alphanate in Immune Tolerance Induction Therapy

Start date: January 3, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, multinational, prospective, single-arm, nonrandomized, open-label study, planned in of approximately 25 male participants with congenital hemophilia A who will receive their first (primary) immune tolerance induction (ITI) treatment with alphanate. The study consists of 2 phases: - An ITI Treatment Phase in which all eligible participants will receive ITI treatment with alphanate for a period of up to 33 months. Upon confirmation of complete immune tolerization, participants will then enter a 12-month Prophylactic Phase. If, after 33 months of ITI, a participants has achieved partial immune tolerance, the participants will enter a 12-month Prophylactic Phase. - A 12-month Prophylactic Phase for all participants who meet the criteria for complete or partial success to continue on a prophylactic dosing regimen of alphanate. Due to limited enrollment, this study was early terminated.